Efficacy and safety of creatine phosphate sodium in the treatment of viral myocarditis: A systematic review and meta-analysis
Wang L, Chen SF, Huang XW, Wu ZY, Zhang QM
PloS one · 1 citation
How it was studied
- Design
- Meta-analysis (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
Based on full-text disclosure statement.
Publication
- Published
- 2025-01-24 · PLoS One · vol. 20 · issue 1 · p. e0317498
- Publisher
- Public Library of Science
- Cited
- 2 citations · more than 56% of similar papers · 0.6× the field average
- References
- 50 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Viral Infections and Immunology Research · Cardiomyopathy and Myosin Studies · Cardiovascular Effects of Exercise
- Keywords
- Phosphocreatine, Cochrane Library, Medicine, Meta-analysis, Internal medicine, Creatine, Creatine kinase, Randomized controlled trial, Gastroenterology, Publication bias
- MeSH
- humans, virus diseases, myocarditis, phosphocreatine, treatment outcome, randomized controlled trials as topic
5 authors
From CN
- Li Wang
- Sufang ChenThe 180th Hospital of PLA; Chinese People's Liberation Army
- Xiwei Huang
- Zhiyang Wu
- Qingmei Zhang · correspondingAffiliated Hangzhou First People's Hospital, Westlake University, School of Medicine
Abstract
Purpose
To systematically evaluate the efficacy and safety of creatine phosphate sodium in the treatment of viral myocarditis, and to provide guidance for its clinical treatment.
Methods
We conducted a search of The Cochrane Library, PubMed, EMbase, and Web of Science databases to retrieve randomized controlled trials (RCTs) on the use of creatine phosphate sodium (CPS) in the treatment of viral myocarditis. The search was conducted up to April 2024. After screening the literature, extracting data, and evaluating the risk of bias in the included studies, we performed a meta-analysis using RevMan 5.4 and Stata17.0 statistical software.
Results
A total of 104 articles were retrieved, and 9 articles with a combined total of 1,116 patients were ultimately included in the meta-analysis. The results of the meta-analysis indicated that the overall efficacy rate in the phosphocreatine sodium treatment group was higher than that in the control group [RR = 1.22, 95%CI (1.15, 1.28), P<0.00001]. Furthermore, post-treatment levels of cardiac troponin I [MD = 0.1, 95%CI (0.07, 0.13), P<0.00001] and creatine kinase isoenzyme [MD = 9.43, 95%CI (7.04,11 .82), P<0 .00001] in the phosphocreatine treatment group were lower compared to those in the control group; both differences between groups were statistically significant. Additionally, there was no significant difference observed in adverse reaction incidence between the phosphocreatine sodium treatment group and conventional treatment group [RR = 1 .07, 95% CI (0 .68, 1 .67), P = O .77].
Conclusion
Creatine phosphate sodium treatment can significantly improve the therapeutic effect of patients with viral myocarditis, and can reduce the levels of cTnI and CK-MB. Compared with conventional treatment, it has good safety.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.